Although the precise effects of YHJGs on AP-1 and NF-κB remain to be experimentally validated, the observed reduction in IL-1β, IL-6, and TNF-α suggests that YHJGs hold promise as a therapeutic agent for stroke-related inflammation. This evidence concerns the gene JUND and stroke disorder.